pCMV-Flag-hMcl-1 Citations (9)
Originally described in: pCMV-Flag-hMcl-1Unpublished
Articles Citing pCMV-Flag-hMcl-1
| Articles |
|---|
| A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. PLoS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571. Epub 2012 Sep 19. PubMed |
| MCL-1 degradation mediated by JNK activation via MEKK1/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189. Wang W, Wang YQ, Meng T, Yi JM, Huan XJ, Ma LP, Tong LJ, Chen Y, Ding J, Shen JK, Miao ZH. Mol Cancer Ther. 2014 Jun;13(6):1480-91. doi: 10.1158/1535-7163.MCT-13-0629. Epub 2014 Mar 31. PubMed |
| HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. Choi YB, Harhaj EW. PLoS Pathog. 2014 Oct 23;10(10):e1004458. doi: 10.1371/journal.ppat.1004458. eCollection 2014 Oct. PubMed |
| Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Wu DW, Chen CY, Chu CL, Lee H. Oncogene. 2015 Apr 27. doi: 10.1038/onc.2015.120. PubMed |
| MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. Oncotarget. 2015 Nov 3;6(34):35202-17. doi: 10.18632/oncotarget.6051. PubMed |
| PAK1 is a novel therapeutic target in tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the PI3K/AKT signaling regardless of EGFR mutation. Wu DW, Wu TC, Chen CY, Lee H. Clin Cancer Res. 2016 May 13. pii: clincanres.2724.2015. PubMed |
| MCL-1 depletion impairs DNA DSB repair and re-initiation of stalled DNA replication forks. Mattoo AR, Pandita RK, Chakraborty S, Charaka V, Mujoo K, Hunt CR, Pandita TK. Mol Cell Biol. 2016 Nov 7. pii: MCB.00535-16. PubMed |
| p62-Mediated mitochondrial clustering attenuates apoptosis induced by mitochondrial depolarization. Xiao B, Deng X, Lim GGY, Zhou W, Saw WT, Zhou ZD, Lim KL, Tan EK. Biochim Biophys Acta. 2017 Jul;1864(7):1308-1317. doi: 10.1016/j.bbamcr.2017.04.009. Epub 2017 Apr 19. PubMed |
| Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. Aka Y, Karakas B, Acikbas U, Basaga H, Gul O, Kutuk O. Int J Biochem Cell Biol. 2021 Aug;137:106028. doi: 10.1016/j.biocel.2021.106028. Epub 2021 Jun 24. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.